AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05436665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UT-DSAEK
Description: The main incision (3.5-5mm) is created at the corneal limbus or via a cornea-scleral tunnel with 2-3 smaller (approx. 1mm) paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber, according to the surgeon's preference. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed. Once the anterior chamber is prepared, OVD or air has been removed, then the eye is ready for the new corneal graft.~The pre-cut corneal tissue delivered by the bank is then gently rinsed and may be stained with 0.06% trypan blue if required. The tissue is loaded into a glide or injector, and pulled into the anterior chamber using a smooth-tipped micro-forceps (e.g., Busin forceps). Once the graft enters the eye, it is lifted to the posterior cornea. The graft is further centred using air (or SF6 Gas) in the anterior chamber.
Study NCT05436665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMEK
Description: The main incision (2.8-3mm) is created superior or temporally at the corneal limbus and is accompanied by 2-3 smaller paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed.~The DMEK roll is poured into a basin and rinsed. The graft is then stained with 0.06% trypan blue to aid in graft visualization. The graft is loaded into an injector and introduced into the anterior chamber. The graft is unrolled using external manoeuvres and once unrolled, it is lifted to the back of the cornea. The eye is then pressurised with a full air fill from 10 to 120 minutes. The pressure is then reduced and the case is completed by suturing any incisions required.
Study NCT04079855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet composition 1
Description: A diet with a specified macronutrient composition different from arms 2 and 3.
Study NCT04079855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet composition 2
Description: A diet with a specified macronutrient composition different from arms 1 and 3.
Study NCT04079855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet composition 3
Description: A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
Study NCT06422936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112
Description: Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
Study NCT05565092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1820
Description: ALXN1820 will be administered subcutaneously.
Study NCT06236347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Paracetamol
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen/Paracetamol
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Description: Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine hydrochloride
Description: Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
Study NCT04963296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
Study NCT05752487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation
Description: Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
Study NCT06773208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZC)
Description: 75 mg/m2 daily, on days 1-7, given IV or SC
Study NCT06773208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg orally daily on days 1-28
Study NCT06774469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: assigned
Description: Group II: (Normal-US Group): The rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power, for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 30 days. Group V: (Osteoarthritis-US group) after two weeks of chemical induction of osteoarthritis, the rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 44 days.
Study NCT06774469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection, Solution
Description: Group III: (Osteoarthritis-induced group): For studying the histological changes of the articular knee joint after osteoarthritis induction in the right knee joint before recovery occur. The patellar ligament will be palpated below the patella and a single intra-articular injection of (MIA lateral to the ligament using an insulin syringe will be performed).~The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL). Saline acts as a vehicle for MIA. The rats will be sacrificed after 14 days of MIA injection (1st day of the experiment).~Group IV: (Osteoarthritis-Recovery group): The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL), Saline acts as a vehicle for MIA and will not receive any medication. The rats will be sacrificed after 44 days of MIA injection (1st day of the experiment).
Study NCT06774469 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ultrasound
Description: Group I:Sham Comparator (Control group): for studying the normal histological structure of the articular knee joint.
Study NCT05358938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
Study NCT05358938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Blockade, Immune
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
Study NCT05358938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Checkpoint Blockade, Immune
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
Study NCT04585789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
Study NCT04585789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
Study NCT04585789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04585789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04585789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.
Study NCT04585789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a (Optional)
Description: PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
Study NCT06773962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: IV infusion.
Study NCT05776069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VGA039
Description: Single doses of VGA039
Study NCT06773962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion.
Study NCT05776069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGA039
Description: Single doses of VGA039
Study NCT05776069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of Placebo
Study NCT05850936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assigned Interventions: IOP-lowering eye drops
Description: IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment.~1. If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added.~2. If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added.~3. The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study.
Study NCT06772012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Description: * Frequency: LLLT was administered 3 times per week.~* Duration: Each session lasted approximately 15-20 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.(50)
Study NCT06772012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Physical Therapy
Description: * Frequency: Orofacial physical therapy sessions were conducted 3 times per week.~* Duration: Each session lasted around 30-40 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.~* Components:~  * Manual Therapy: Included techniques such as joint mobilization, soft tissue manipulation, and muscle stretching.~ * Therapeutic Exercises: Focused on strengthening, coordination, and improving mobility of the masticatory muscles.~ * Postural Training: Addressed poor posture and cervical muscle spasm.(50)
Study NCT06771466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound-Guided Erector Spinae Plane Block (group E)
Description: The curvilinear ultrasound transducer should be placed in a cephalocaudal orientation over the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level. The transverse process will be more superficial and wider, while the rib will be deeper and thinner. Upon verification of the transverse process, the trapezius muscle, rhomboid major muscle (if performing at T5 level or higher), and erector spinae muscle should be identified superficial to the transverse process. The Tuohy needle should be inserted superior to the ultrasound probe using an in-plane approach in the cephalad to caudal direction.
Study NCT06771466 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral Ultrasound-guided Quadratus Lumborum, Lateral approach (group Q)
Description: With the patient positioned in the lateral position, scanning is usually started at the mid-axillary line between the iliac crest and subcostal margin, moving the probe posteriorly until tapering of the three abdominal muscle layers and appearance of fascia transversalis and QL muscle are observed. The fascia transversalis usually appears as a hyperechoic layer, which forms a safe landmark to separate the muscle layers from the peri-nephric fat and the abdominal contents
Study NCT06635889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
Study NCT06635889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo of 50 ml of Normal Saline
Study NCT05974254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electroacupuncture
Study NCT05480124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS brain stimulation treatment
Description: Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
Study NCT05480124 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation treatment
Description: Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
Study NCT06484062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06484062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT06484062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirtuvivint
Description: Given PO
Study NCT06484062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT06484062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06484062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant. Experimental. Administered orally
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen. Comparator. Administered orally
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole. Comparator. Administered orally
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole. Comparator. Administered orally
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane. Comparator. Administered orally
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Abemaciclib adjuvant treatment Administered orally
Study NCT05952557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib adjuvant treatment Administered orally
Study NCT06444516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123300 ocular lubricant
Description: Investigational ocular lubricant
Study NCT06298227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management with Paracerol® and IV PCA with Talinat®
Description: In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.
Study NCT06298227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
Study NCT06298227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum plane block
Description: QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
Study NCT06262919 — intervention group
Intervention type: DRUG
Intervention: Tafinlar/Mekinist
Description: There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT06157385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Medicine
Description: The CM group will receive virtually-delivered cooking demonstration videos every week and nutrition education videos every other week. The cooking demonstrations will provide them with visual instructions on how to incorporate lean beef into their diet. The nutrition education videos will be developed using the Nutrition Care Manual from the Academy of Nutrition and Dietetics and will cover the importance of maintaining adequate protein intake and ways to enhance it in the diet.
Study NCT06157385 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The CN group will receive virtually-delivered recipes every week centered on lean beef intake.
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard of care chemotherapy regimen
Study NCT05212246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Imiquimod cream
Description: Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard of care chemotherapy regimen